MedPath

Treatment of Functional Dyspepsia (Indigestion) with Unani medicine Majoone-Sangdana Murgh

Phase 3
Conditions
Health Condition 1: K30- Functional dyspepsia
Registration Number
CTRI/2019/02/017801
Lead Sponsor
Central Council for Research in Unani Medicine CCRUM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

· Patients of either sex in the age group of 18-60

· Patients meeting the Rome III diagnostic criteria for PDS

Exclusion Criteria

· Presence of GI ulcer, erosive gastritis, atrophic gastritis, severe dysplasia of gastric mucosa

or suspicious malignant lesion.

· Having overlap syndrome combined with gastro esophageal reflux disease or irritable

bowel syndrome

· Having alarm symptoms (weight loss, black or tar stool, dysphasia, etc.)

· Having any systemic disease (diseases of heart, lung, liver or kidney) or mental illness

· History of surgery related with the gastrointestinal tract more than six months ago

· Taking drugs which may affect the gastro intestinal tract, such as non-steroidal antiinflammatory

drugs and aspirin

· Known Allergy to the experimental medications

· Pregnant and breastfeeding

· Refusing to sign the informed consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in signs and symptoms of Duâ??f al-Miâ??da (Functional Dyspepsia)Timepoint: 6 weeks
Secondary Outcome Measures
NameTimeMethod
Investigations will be done at baseline and end of treatmentTimepoint: 6 weeks
© Copyright 2025. All Rights Reserved by MedPath